10:45 AM
 | 
Jan 12, 2018
 |  BC Extra  |  Company News

PTAB denies Concert's challenge to Jakafi patent

Concert Pharmaceuticals Inc. (NASDAQ:CNCE) lost $7.53 (27%) to $20.15 on Friday after the U.S. Patent Trial and Appeal Board declined the company’s post grant review (PGR) petition challenging U.S. Patent No. 9,662,335, which covers Jakafi ruxolitinib from Incyte Corp. (NASDAQ:INCY). Concert said it does not expect the decision to affect clinical timelines for CTP-543,...

Read the full 246 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >